Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus

SYSTEMIC LUPUS ERYTHEMATOSUS (M PETRI, SECTION EDITOR)

DOI: 10.1007/s11926-013-0337-z

Cite this article as:
Wallace, D.J. Curr Rheumatol Rep (2013) 15: 337. doi:10.1007/s11926-013-0337-z
Part of the following topical collections:
  1. Topical Collection on Systemic Lupus Erythematosus

Abstract

Belimumab has recently been approved, and several other types of biological therapy with different mechanisms of action are currently in phase II and III studies. This review puts these approaches in context, emphasizing mechanistic categories and clinical trial designs. Most of the promising approaches involve B cell depletion or modulation. Post-approval experience with belimumab is critically reviewed.

Keywords

Biologicals Targeted therapy Systemic lupus erythematosus SLE FDA Treatment Cutaneous lupus Belimumab Epratuzumab T cell inhibition 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Cedars-Sinai Medical CenterDavid Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.West HollywoodUSA

Personalised recommendations